Market Research Logo

Liver Fibrosis - Pipeline Review, H2 2016

Liver Fibrosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Liver Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
    • The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
    • The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Liver Fibrosis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Liver Fibrosis Overview
    Therapeutics Development
    Pipeline Products for Liver Fibrosis - Overview
    Pipeline Products for Liver Fibrosis - Comparative Analysis
    Liver Fibrosis - Therapeutics under Development by Companies
    Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes
    Liver Fibrosis - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Liver Fibrosis - Products under Development by Companies
    Liver Fibrosis - Products under Investigation by Universities/Institutes
    Liver Fibrosis - Companies Involved in Therapeutics Development
    Advinus Therapeutics Ltd
    Akarna Therapeutics Ltd.
    Angion Biomedica Corp.
    Asubio Pharma Co., Ltd.
    aTyr Pharma, Inc.
    Beijing Kawin Technology Share-Holding Co., Ltd.
    BioLineRx, Ltd.
    Bioneer Corporation
    BiOrion Technologies B.V.
    Bird Rock Bio, Inc.
    Bristol-Myers Squibb Company
    Cellmid Limited
    ContraVir Pharmaceuticals, Inc.
    Dicerna Pharmaceuticals, Inc.
    Digna Biotech, S.L.
    Dr. Falk Pharma GmbH
    Dynavax Technologies Corporation
    Evotec AG
    Galectin Therapeutics, Inc.
    Genfit SA
    Gilead Sciences, Inc.
    GNI Group Ltd.
    HEC Pharm Co., Ltd.
    Immuron Limited
    Intercept Pharmaceuticals, Inc.
    INVENT Pharmaceuticals, Inc.
    Isarna Therapeutics GmbH
    KineMed, Inc.
    LG Life Science LTD.
    Nitto Denko Corporation
    Pfizer Inc.
    Pharmaxis Limited
    Promedior, Inc.
    Promethera Biosciences S.A.
    ProMetic Life Sciences Inc.
    Ribomic Inc.
    RXi Pharmaceuticals Corporation
    Silence Therapeutics Plc
    TCM Biotech International Corp
    Vascular Biogenics Ltd.
    Virobay Inc.
    XTuit Pharmaceuticals, Inc.
    Liver Fibrosis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ANG-3070 - Drug Profile
    ANG-3281 - Drug Profile
    Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile
    Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile
    Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
    Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile
    Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile
    ASB-14780 - Drug Profile
    BL-1210 - Drug Profile
    BMS-986171 - Drug Profile
    BOT-162 - Drug Profile
    BOT-191 - Drug Profile
    CAB-102 - Drug Profile
    CPI-43132 - Drug Profile
    CT-140 - Drug Profile
    DB-036 - Drug Profile
    Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile
    Drugs for Tissue Fibrosis - Drug Profile
    DV-1079 - Drug Profile
    F-351 - Drug Profile
    Gene Therapy for Liver Fibrosis - Drug Profile
    GMCT-01 - Drug Profile
    GRMD-02 - Drug Profile
    GS-444217 - Drug Profile
    HEC-585 - Drug Profile
    HepaStem - Drug Profile
    IMM-124E - Drug Profile
    INT-767 - Drug Profile
    INV-240 - Drug Profile
    ISTH-0047 - Drug Profile
    KW-0 - Drug Profile
    KW-012 - Drug Profile
    LC-280126 - Drug Profile
    melittin - Drug Profile
    Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile
    MOR-8457 - Drug Profile
    MRI-1867 - Drug Profile
    ND-L02s0201 - Drug Profile
    norursodeoxycholic acid - Drug Profile
    noscapine - Drug Profile
    PBI-4050 - Drug Profile
    PRM-151 - Drug Profile
    Proteins for Liver Fibrosis - Drug Profile
    PXS-4820 - Drug Profile
    PXS-5033A - Drug Profile
    RBM-006 - Drug Profile
    Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile
    RXI-209 - Drug Profile
    RYI-018 - Drug Profile
    selonsertib - Drug Profile
    selonsertib + simtuzumab - Drug Profile
    Small Molecule for Liver Fibrosis - Drug Profile
    Small Molecule for Liver Fibrosis - Drug Profile
    Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile
    Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
    Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile
    Small Molecules for Hepatic Fibrosis - Drug Profile
    Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
    Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
    Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
    TCM-808FB - Drug Profile
    TGFTX-4 - Drug Profile
    VB-201 - Drug Profile
    VB-703 - Drug Profile
    VBY-376 - Drug Profile
    VBY-825 - Drug Profile
    Liver Fibrosis - Dormant Projects
    Liver Fibrosis - Discontinued Products
    Liver Fibrosis - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Liver Fibrosis, H2 2016
    Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Investigation by Universities/Institutes, H2 2016
    Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016
    Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016
    Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
    Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016
    Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016
    Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016
    Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016
    Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016
    Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
    Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016
    Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016
    Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
    Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016
    Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016
    Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
    Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016
    Liver Fibrosis - Pipeline by Evotec AG, H2 2016
    Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
    Liver Fibrosis - Pipeline by Genfit SA, H2 2016
    Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
    Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016
    Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
    Liver Fibrosis - Pipeline by Immuron Limited, H2 2016
    Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
    Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
    Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
    Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016
    Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016
    Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016
    Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016
    Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
    Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016
    Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016
    Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
    Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016
    Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
    Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016
    Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016
    Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016
    Liver Fibrosis - Pipeline by Virobay Inc., H2 2016
    Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Liver Fibrosis - Dormant Projects, H2 2016
    Liver Fibrosis - Dormant Projects (Contd..1), H2 2016
    Liver Fibrosis - Dormant Projects (Contd..2), H2 2016
    Liver Fibrosis - Dormant Projects (Contd..3), H2 2016
    Liver Fibrosis - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Liver Fibrosis, H2 2016
    Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report